Al Garfall

NIH scientists have a cancer breakthrough. Layoffs are delaying it. A big step forward in cancer therapy has been slowed by layoffs and new restrictions at the National Institutes of Health, where it was developed.

wapo.st/42yttHQ

Opinion | I Shudder to Imagine Kennedy Running Our Health Agencies. (Gift Article) We have to go toe-to-toe with this administration and resist its attacks on public health.

Explore this gift article from The New York Times. You can read it for free without a subscription. www.nytimes.com/2025/02/13/o...

These cases occurred despite guideline-compliant ID prophylaxis. Two required removal of orthopedic hardware. Two were identified during evaluation of PET/CT abnormalities (bone, LN), highlighting need for biopsy if PET/CT is not congruent with serum MM markers.

Important observations by our group @penncancer.bsky.social, led by Dr. Matthew Ho, on non-tuberculous mycobacterial infections in multiple myeloma patients on teclistamab: haematologica.org/article/view...

The case for clinical trial abundance A supply-side reform agenda for one of our most urgent problems

open.substack.com/pub/matthewy...

go.bsky.app/REknptc

It was wonderful to get together in-person with our multi-site team working on the LimiTec trial of limited-duration teclistamab therapy for rel/ref #myeloma at #ASH24! Thanks to Leukemia & Lymphoma Society for supporting our trial! clinicaltrials.gov/study/NCT059... @myelomateacher.bsky.social

Penn Medicine partners with Mark Cuban’s Cost Plus Drugs Penn Medicine has partnered with Mark Cuban's Cost Plus Drug Company through its innovative Cost Plus Marketplace in a strategic alliance that will allow Penn Medicine to secure the top 100 most frequ...

Not every day a leading US academic health system partners with @costplusdrugs.com, bypassing PBMs, to save drug costs for their patients
@pennmedicine.bsky.social + @mcuban.bsky.social
www.pennmedicine.org/news/news-re... a 1st-of-its-kind deal

Thank you! Terrific session, thank you for getting us all together.

Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients

Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch

Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
www.nature.com/articles/s41...

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML Key Points. CD70 targeted CAR-T cells secreting a CD33 T-cell engaging antibody molecule eradicate CD33 or CD70 deficient AML

ashpublications.org/blood/articl...

Done 👍

Re-posting this starter pack on multiple myeloma, now updated with a few more accounts. Please share and let me know if I’m missing anyone!

go.bsky.app/REknptc

TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function Modulation of exhausted CD8+ T cell differentiation by targeting TET2 improves therapeutic potential of CAR T cells in cancer.

🚨NEW🧪: TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function - #CARTCell #immunotherapy #TCell #tcellrx #immunology www.science.org/doi/10.1126/...

If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW

Nikhil, added you to this “starter pack.” You can find other myeloma folks there too.

go.bsky.app/REknptc

Can email ashregistration@spargoinc.com

Details here:
www.hematology.org/meetings/ann...

Can also convert to virtual attendance.

#ASH24 Peripheral Residual Disease (PRD) by mass spect and MRD by NGF in NDMM (GEM2017FIT Trial)
-79.6% concordance
-integration of PRD into routine clinical practice may be beneficial for all elderly pts #mmsm ash.confex.com/ash/2024/web...

Hi all, I created this starter pack of accounts related to multiple myeloma research and clinical care. Please let me know whom I'm missing, and I will update! go.bsky.app/REknptc

Ha, this was fun to read because my son is a freshman there now and having a little issue about a newspaper story.